Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9897973 | PMC |
| http://dx.doi.org/10.1016/j.jinf.2023.01.036 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A systematic review and meta-analysis of adverse events following measles-containing vaccines in infants less than 12 months of age.
Vaccine
January 2025
The Child and Adolescent Clinic, Juliane Marie Center, The Danish National University Hospital "Rigshospitalet", Copenhagen, Capital Region of Denmark, Denmark; Institute for Clinical Medicine, University of Copenhagen, Denmark.
Background: Lowering the age for receiving the first dose of a measles-containing vaccine (MCV1) has been suggested to close the emerging immunity gap in infants. However, tolerability remains one of the main concerns for vaccine-hesitant parents. We conducted a systematic review and meta-analysis of reactogenicity following MCV1 in infants under 12 months of age.
View Article and Find Full Text PDFGastrointestinal Shedding of Rubulaviruses from Egyptian Rousette Bats: Temporal Dynamics and Spillover Implications.
Microorganisms
December 2024
Centre for Viral Zoonoses, Department of Medical Virology, School of Medicine, Faculty of Health Sciences, University of Pretoria, Pretoria 0001, South Africa.
Bats are recognized as reservoirs for diverse paramyxoviruses, some of which are closely related to known human pathogens or directly implicated in zoonotic transmission. The emergence of the zoonotic Sosuga virus (SOSV) from Egyptian rousette bats (ERBs), which caused an acute febrile illness in a reported human case in Africa, has increased the focus on the zoonotic potential of the subfamily. Previous studies identified human parainfluenza virus 2 (HPIV2)- and mumps (MuV)-related viruses in ERBs from South Africa, with HPIV2-related viruses restricted to gastrointestinal samples, an underexplored target for rubulavirus biosurveillance, suggesting that sample-type bias may have led to their oversight.
View Article and Find Full Text PDFSeronegative Vaccinees May Not Benefit From Multiple Booster Doses of MMR Vaccine in Restoring Immunity.
J Med Virol
December 2024
Department of Medical Biotechnologies, University of Siena, Siena, Italy.
Despite the availability of a highly efficacious vaccine, a global resurgence of measles infections has occurred, largely due to decreased vaccination coverage and waning immunity following the two-dose vaccination schedule. This study aims to assess the cellular immune response in individuals who did not respond to the two-dose MMR vaccine and evaluate the efficacy and durability of immune responses after booster doses. An observational study was conducted involving 24 individuals who were seronegative for measles years after completing the two-dose MMR vaccine schedule.
View Article and Find Full Text PDFInequalities in uptake of childhood vaccination in England, 2019-23: longitudinal study.
BMJ
December 2024
Department of Public Health, Policy and Systems, Institute of Population Health, University of Liverpool, Liverpool, UK.
Objective: To quantify changes in inequalities in uptake of childhood vaccination during a period of steadily declining overall childhood vaccination rates in England.
Design: Longitudinal study.
Setting: General practice data for five vaccines administered to children (first and second doses of the measles, mumps, and rubella vaccine (MMR1 and MMR2, respectively), rotavirus vaccine, pneumococcal conjugate vaccine (PCV) booster, and six-in-one (DTaP/IPV/Hib/HepB) vaccine covering diphtheria, tetanus, pertussis, polio, type b, and hepatitis B) from the Cover of Vaccination Uptake Evaluated Rapidly dataset in England.
Mumps outbreak in Zimbabwe: The case for universal MMR vaccination in Africa.
Vaccine X
December 2024
School of Health Systems and Public Health, University of Pretoria, Pretoria, South Africa.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!